Download PDF
Nervenheilkunde 2022; 41(05): 320-325
DOI: 10.1055/a-1755-7554
Schwerpunkt

Anorexia nervosa – eine metabolisch-psychiatrische Erkrankung?

Neue Impulse für alternative TherapieansätzeAnorexia nervosa – a disorder of metabolic-psychiatric origin?New stimuli for the development of alternative treatment methods
Beate Herpertz-Dahlmann
1   Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters der RWTH Aachen
,
Jochen Seitz
1   Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters der RWTH Aachen
,
Brigitte Dahmen
1   Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters der RWTH Aachen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die Anorexia nervosa (AN) ist die psychische Erkrankung mit der höchsten Mortalität. Individuen, die im Jugendalter erkranken, leiden durchschnittlich über 10 Jahre an dieser Störung. Obwohl die klinische Erfahrung und internationale sowie nationale Studien auf einen unzureichenden Heilungserfolg hinweisen, wird in Deutschland meist an der traditionellen langdauernden stationären Behandlung festgehalten. Studien zur Erforschung der Ätiologie haben neue Erkenntnisse gebracht. Der vorliegende Artikel will beispielhaft neue biologische und psychologische Interventionen aufzeigen, die die Prognose dieser Erkrankung verbessern könnten. Dazu gehören therapeutische Strategien, die auf das Darm-Mikrobiom und damit auf die Darm-Gehirn-Achse Einfluss nehmen, eine neue experimentelle Behandlung mit Metreleptin (rekombinantes menschliches Leptin) sowie ein neues Behandlungssetting, das Home-Treatment. Nach erfolgreichen Pilotstudien soll in randomisiert-kontrollierten Studien herausgefunden werden, wie eine „personalisierte Behandlung“ der AN in Abhängigkeit von Schweregrad und Krankheitsdauer durchgeführt werden könnte.

ABSTRACT

Anorexia nervosa has the highest mortality of all psychiatric disorders. Young people with an onset of the disease in adolescence suffer on average for more than ten years from an eating disorder. Advancing knowledge of the aetiology of this disorder could inform biological and psychological interventions which might improve the prognosis of this long-lasting illness. This article will present three examples of new therapeutic strategies which 1) target the gut microbiome and the gut-brain axis, 2) explore the effects of a new pharmacological agent, the experimental application of metreleptin (recombinant human leptin) and 3) investigate a new treatment setting which involves the patient, her caregivers and her home environment (home treatment). After pilot studies with satisfactory results, it is the aim of current ongoing randomized controlled trials to find out for which patients at what stage of the illness these treatments might improve the outcome of this disabling disorder.

Schlüsselwörter

Anorexia nervosa - Adoleszenz - Behandlung - Darmmikrobiom - Metreleptin - Home-Treatment

Key words

Anorexia nervosa - adolescence - treatment - gut microbiome - metreleptin - home treatment


Publication History

Article published online:
05 May 2022

© 2022. Thieme. All rights reserved.

© Georg Thieme Verlag KG Stuttgart · New York
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dobrescu SR, Dinkler L, Gillberg C. et al Anorexia nervosa: 30-year outcome. Br J Psychiatry 2019: 1-8 DOI: 10.1192/bjp.2019.113
    CrossrefPubMedGoogle Scholar
  • 2 Hebebrand J, Bulik CM. Critical appraisal of the provisional DSM-5 criteria for anorexia nervosa and an alternative proposal. Int J Eat Disord 2011; 44: 665-678 DOI: 10.1002/eat.20875.
    CrossrefPubMedGoogle Scholar
  • 3 Kaye WH, Bulik CM. Treatment of Patients With Anorexia Nervosa in the US-A Crisis in Care. JAMA Psychiatry 2021; 78: 591-592
    CrossrefPubMedGoogle Scholar
  • 4 Zipfel S, Schmidt U, Giel KE. The hidden burden of eating disorders during the COVID-19 pandemic. Lancet Psychiatry 2022; 09: 9-11
    CrossrefPubMedGoogle Scholar
  • 5 Bulik CM, Carroll IM, Mehler P. Reframing anorexia nervosa as a metabo-psychiatric disorder. Trends Endocrinol Metab 2021; 32: 752-761 DOI: 10.1016/j.tem.2021.07.010.
    CrossrefPubMedGoogle Scholar
  • 6 Watson HJ, Yilmaz Z, Thornton LM. et al Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat Genet 2019 DOI: 10.1038/s41588-019-0439-2
    CrossrefPubMedGoogle Scholar
  • 7 Turnbaugh PJ, Ley RE, Mahowald MA. et al An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 DOI: 10.1038/nature05414.
    CrossrefPubMedGoogle Scholar
  • 8 Smith MI, Yatsunenko T, Manary MJ. et al Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548-554
    CrossrefPubMedGoogle Scholar
  • 9 Hata T, Miyata N, Takakura S. et al The Gut Microbiome Derived From Anorexia Nervosa Patients Impairs Weight Gain and Behavioral Performance in Female Mice. Endocrinology 2019; 160: 2441-2452
    CrossrefPubMedGoogle Scholar
  • 10 Di Lodovico L, Mondot S, Doré J. et al Anorexia nervosa and gut microbiota: A systematic review and quantitative synthesis of pooled microbiological data. Prog Neuropsychopharmacol Biol Psychiatry 2021; 106: 110114 DOI: 10.1016/j.pnpbp.2020.110114.
    CrossrefPubMedGoogle Scholar
  • 11 Schulz N, Belheouane M, Dahmen B. et al Gut microbiota alteration in adolescent anorexia nervosa does not normalize with short-term weight restoration. Int J Eat Disord 2021; 54: 969-980
    CrossrefPubMedGoogle Scholar
  • 12 Mack I, Cuntz U, Grämer C. et al Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. Scientific reports 2016; 06: 26752
    CrossrefPubMedGoogle Scholar
  • 13 Kleiman SC, Watson HJ, Bulik-Sullivan EC. et al The intestinal microbiota in acute anorexia nervosa and during renourishment: relationship to depression, anxiety, and eating disorder psychopathology. Psychosomatic medicine 2015; 77: 969
    CrossrefPubMedGoogle Scholar
  • 14 Seitz J, Keller L, Trinh S. et al Darmmikrobiom und Anorexia nervosa,Der Zusammenhang von Mikrobiom und Darm-Gehirn-Interaktion im Kontext der Anorexia nervosa. Nervenarzt 2020; 91: 1115-1121
    CrossrefPubMedGoogle Scholar
  • 15 Hedman A, Breithaupt L, Hübel C. et al Bidirectional relationship between eating disorders and autoimmune diseases. J Child Psychol Psychiatry 2018 DOI: 10.1111/jcpp.12958
    CrossrefPubMedGoogle Scholar
  • 16 Herpertz S, Fichter M, Herpertz-Dahlmann B. et al S3-Leitlinie Diagnostik und Behandlung der Essstörungen. Berlin: Springer; 2019
    CrossrefGoogle Scholar
  • 17 David LA, Maurice CF, Carmody RN. et al Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-563
    CrossrefPubMedGoogle Scholar
  • 18 Maier L, Pruteanu M, Kuhn M. et al Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555: 623
    CrossrefPubMedGoogle Scholar
  • 19 Costantini L, Molinari R, Farinon B. et al Impact of Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci 2017: 18 DOI: 10.3390/ijms18122645
    CrossrefPubMedGoogle Scholar
  • 20 Mauler B, Dubben S, Pawelzik M. et al Hypercaloric diets differing in fat composition have similar effects on serum leptin and weight gain in female subjects with anorexia nervosa. Nutr Res 2009; 29: 1-7
    CrossrefPubMedGoogle Scholar
  • 21 Carolini C. Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System. Mar Drugs 2019; 17: E374 DOI: 10.3390/md17060374.
    CrossrefPubMedGoogle Scholar
  • 22 Bremner JD, Moazzami K, Wittbrodt MT. et al Diet, Stress and Mental Health. Nutrients 2020; 12: E2428 DOI: 10.3390/nu12082428.
    CrossrefPubMedGoogle Scholar
  • 23 Gröbner E-M, Zeiler M, Fischmeister FPS. et al The effects of probiotics administration on the gut microbiome in adolescents with anorexia nervosa-A study protocol for a longitudinal, double-blind, randomized, placebo-controlled trial. Eur Eat Disord Rev 2022; 30: 61-74
    CrossrefPubMedGoogle Scholar
  • 24 Bagga D, Aigner CS, Reichert JL. et al Influence of 4-week multi-strain probiotic administration on resting-state functional connectivity in healthy volunteers. European journal of nutrition 2018: 1-7
    PubMedGoogle Scholar
  • 25 Exner C, Hebebrand J, Remschmidt H. et al Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa. Mol Psychiatry 2000; 05: 476-481
    CrossrefPubMedGoogle Scholar
  • 26 Milos G, Antel J, Kaufmann L-K. et al Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psychiatry 2020; 10: 303 DOI: 10.1038/s41398-020-00977-1.
    CrossrefPubMedGoogle Scholar
  • 27 Antel J, Tan S, Grabler M. et al Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism. Eur Child Adolesc Psychiatry 2021 DOI: 10.1007/s00787-021-01778-7
    CrossrefPubMedGoogle Scholar
  • 28 Madden S, Miskovic-Wheatley J, Wallis A. et al A randomized controlled trial of in-patient treatment for anorexia nervosa in medically unstable adolescents. Psychol Med 2015; 45: 415-427 DOI: 10.1017/S0033291714001573.
    CrossrefPubMedGoogle Scholar
  • 29 Steinhausen H-C, Grigoroiu-Serbanescu M, Boyadjieva S. et al Course and predictors of rehospitalization in adolescent anorexia nervosa in a multisite study. Int J Eat Disord 2008; 41: 29-36
    CrossrefPubMedGoogle Scholar
  • 30 Stuhldreher N, Wild B, König H-H. et al Determinants of direct and indirect costs in anorexia nervosa. Int J Eat Disord 2015; 48: 139-146
    CrossrefPubMedGoogle Scholar
  • 31 Schlegl S, Voderholzer U, Maier J. et al Wirksamkeit, Moderatoren und Mediatoren manualisierter familienbasierter Therapie bei Jugendlichen mit Essstörungen: Eine systematische Übersichtsarbeit. Psychother Psychosom Med Psychol 2020; 70: 112-121
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Herpertz-Dahlmann B, Schwarte R, Krei M. et al Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial. The Lancet 2014; 383: 1222-1229
    CrossrefPubMedGoogle Scholar
  • 33 Herpertz-Dahlmann B, Dempfle A.. Treatment setting matters – an evaluation of prognostic factors for outcome in adolescent AN. Vortrag 22nd meeting of the Eating Disorder Research Society, New York. 2016
    PubMedGoogle Scholar
  • 34 Walsh BT, Xu T, Wang Y. et al Time Course of Relapse Following Acute Treatment for Anorexia Nervosa. Am J Psychiatry 2021; 178: 848-853
    CrossrefPubMedGoogle Scholar
  • 35 Herpertz-Dahlmann B, Borzikowsky C, Altdorf S. et al ’Therapists in action’-Home treatment in adolescent anorexia nervosa: A stepped care approach to shorten inpatient treatment. Eur Eat Disord Rev 2021 DOI: 10.1002/erv.2755
    CrossrefPubMedGoogle Scholar
  • 36 Heider KS, Dempfle A, Altdorf S. et al Motivation to Change in the Course of a Pilot Study of a Step-Down Treatment Approach of Inpatient and Anorexia Nervosa-Specific Home Treatment and Its Effects on Treatment Outcome. Front Psychiatry 2021; 12: 693103 DOI: 10.3389/fpsyt.2021.693103.
    CrossrefPubMedGoogle Scholar
  • 37 Giel KE, Behrens SC, Schag K. et al Efficacy of post-inpatient aftercare treatments for anorexia nervosa: a systematic review of randomized controlled trials. J Eat Disord 2021; 09: 129 DOI: 10.1186/s40337-021-00487-5.
    CrossrefPubMedGoogle Scholar
  • 38 Bulik CM. From Awareness to Action: An Urgent Call to Address the Inadequacy of Treatment for Anorexia Nervosa. Am J Psychiatry 2021; 178: 786-788 DOI: 10.1176/appi.ajp.2021.21070697.
    CrossrefPubMedGoogle Scholar